EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 17th, 2022 • Allarity Therapeutics, Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement (this “Agreement”) is entered into as of January 2, 2022 (the “Effective Date”) by and between Allarity Therapeutics A/S, a company incorporated under the laws of Denmark, with its principal place of business at Venlighedsvej 1, DK-2970 Hørsholm, Denmark (“Allarity”), and Oncoheroes Biosciences Inc., a Delaware corporation, with its principal place of business at 62 Cypress St. #5, Brookline, MA 02445 (“Oncoheroes”). Allarity and Oncoheroes are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LIPLACIS SUPPORT AGREEMENTLiplacis Support Agreement • May 17th, 2022 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
THIS LIPLACIS SUPPORT AGREEMENT (this “Agreement”), dated as of March 28, 2022 (the “Effective Date”), is by and among Allarity Therapeutics Europe ApS, a company organized and existing under the laws of Denmark, with its principal place of business Venlighedsvej 1 DK-2970 Hørsholm, (“Allarity ApS”), Allarity Therapeutics A/S (formerly known as Medical Prognosis Institute A/S), Venlighedsvej 1 DK-2970 Hørsholm (hereinafter “Allarity A/S”, and together with Allarity ApS, “Allarity”), Smerud Medical Research International AS, a company organized and existing under the laws of Norway having an address of Thunes Vei 2, N-0274 Oslo, Norway (“Smerud”), Chosa, ApS, a company organized and existing under the laws of Denmark having an address of Frederiksgade 17, DK-1265 København K (“Chosa”), and LiPlasome Pharma ApS, a company organized and existing under the laws of Denmark having an address of Tabletvej 1 DK-7100 Vejle (“LiPlasome”). Allarity, Smerud, Chosa, and LiPlasome are each referred
Assignment and Assumption AgreementAssignment and Assumption Agreement • May 17th, 2022 • Allarity Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Assignment and Assumption Agreement (the “Agreement”), effective as of January 2, 2022 (the “Effective Date”), is by and between Allarity Therapeutics A/S, an Aktieselskab organized under the laws of Denmark (“Assignor”), and Allarity Therapeutics, Inc., a Delaware corporation (“Assignee”).
ContractLicense Agreement • May 17th, 2022 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
